The aim of this Challenge is to develop an in vitro model of the human liver that is metabolically  and  immunologically-competent  for  the  routine  assessment  of Yellow Fever (YF) vaccine attenuation.

The vaccine is based on a live-attenuated virus derived from a pathogenic strain of YF virus and is currently assessed in non-human primates (NHPs), specifically cynomolgus macaques. Existing in vitro liver models are not fit for viral testing in a pharmaceutical context due to a lack of immune competency. A non-exhaustible or easily renewable source of cells, with a characterised origin is required. The model must be compatible with automated distribution and multiple sample analysis, as well as the constraints linked to manipulations of pathogenic agents 

Phase 1: Technical feasibility

• Projects can range in size up to a maximum cost of £100,000 and should last up

to 6 months.

Phase 2: Prototype development and evaluation

• Projects can range in size up to a total cost of £1,000,000 and should last up to

3 years.

Register here until 7th November 2018 at 12pm. For more information, read the

guidance

Per al vostre coneixement, la compra pública d’innovació (CPI) és una actuació administrativa de foment de la innovació, orientada a potenciar el desenvolupament de solucions innovadores des de la demanda, mitjançant l’instrument de la compra pública.

Periòdicament es publica i actualitza aquelles licitacions possibles de compra, dels quals hi poden participar tant petites i mitjanes empreses com organismes públics. Si voleu informació més detellada podeu visitar l’enllaç d’ACCIÓ.

Finalment si  us interessa alguna oferta o teniu qualsevol consulta podeu contactar amb la Unitat de Valorització. (valoritzacio@udg.edu)